Your Messages Inbox
Your Article Summary
See Latest ArticlesGolimumab (Simponi): Anti-TNF-alpha mAb approved for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
Formulary , 06/09/09
Tumor necrosis factor (TNF)-alpha is a mediator of articular inflammation in chronic inflammatory diseases. Golimumab is a human monoclonal antibody that binds to human TNF-alpha, thus inhibiting its activity. Golimumab was approved on April 2009, for use alone or in combination with methotrexate for the treatment of adult patients with active psoriatic arthritis, for use in combination with methotrexate for the treatment of adult patients with moderately to severely active rheumatoid arthritis, and for the treatment of adult patients with active ankylosing spondylitis.
Today in Drug/Product Approvals...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09
Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09
Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09
Article Search
Sponsor